18426 Brain imaging differentiation study

• Research type

  Research Study

• Full title

  A Phase I, randomized, placebo-controlled, open-label, three period crossover study to investigate the effect of darolutamide and enzalutamide on cerebral blood flow in healthy male volunteers.

• IRAS ID

  249835

• Contact name

  Ndabezinhle Mazibuko

• Contact email

  ndabezinhle.mazibuko@kcl.ac.uk

• Eudract number

  2018-001599-39

• Duration of Study in the UK

  0 years, 11 months, 9 days

• Research summary

  The primary objective of this study is to investigate drug-induced changes in the blood flow in the brain during single dose treatment with darolutamide or enzalutamide compared to placebo and compared to each other.

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  18/SC/0433

• Date of REC Opinion

  4 Sep 2018

• REC opinion

  Favourable Opinion